Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody
出版年份 2023 全文链接
标题
Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody
作者
关键词
-
出版物
BREAST
Volume -, Issue -, Pages 103597
出版商
Elsevier BV
发表日期
2023-11-01
DOI
10.1016/j.breast.2023.103597
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Margetuximab in HER2-positive metastatic breast cancer
- (2023) William J Gradishar et al. Future Oncology
- Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
- (2023) Naomi Dempsey et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial
- (2022) Zhenzhen Liu et al. EUROPEAN JOURNAL OF CANCER
- LBA19 Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
- (2022) B. Xu et al. ANNALS OF ONCOLOGY
- Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
- (2022) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
- (2021) Hope S. Rugo et al. JAMA Oncology
- Current and Future Management of HER2-Positive Metastatic Breast Cancer
- (2021) Olga Martínez-Sáez et al. JCO Oncology Practice
- A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action
- (2020) Xuesai Zhang et al. MOLECULAR IMMUNOLOGY
- Maternal Embryonic Leucine Zipper Kinase Promotes Tumor Growth and Metastasis via Stimulating FOXM1 Signaling in Esophageal Squamous Cell Carcinoma
- (2020) Liang Chen et al. Frontiers in Oncology
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
- (2020) Binghe Xu et al. BREAST CANCER RESEARCH AND TREATMENT
- Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I– III HER2‐Positive Breast Cancer: A Phase II Clinical Trial
- (2020) Juncheng Xuhong et al. ONCOLOGIST
- The US Food and Drug Administration's Real‐World Evidence Framework: A Commitment for Engagement and Transparency on Real‐World Evidence
- (2019) M. Khair ElZarrad et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience
- (2019) Nicolò Matteo Luca Battisti et al. BREAST CANCER RESEARCH AND TREATMENT
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
- (2018) Sara A Hurvitz et al. LANCET ONCOLOGY
- Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China
- (2017) Jianbin Li et al. ONCOLOGIST
- A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients
- (2015) Xinna Zhou et al. SpringerPlus
- Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer
- (2014) Z. Eroglu et al. ONCOLOGIST
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now